0000000000696630

AUTHOR

Lodewijk A.a. Brosens

showing 3 related works from this author

Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters

2021

Contains fulltext : 245221.pdf (Publisher’s version ) (Open Access) BACKGROUND: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related insulinomas and assessed factors associated with prognosis. METHODS: Patients who underwent resection of a multiple endocrine neoplasia ty…

AdultDiagnostic ImagingMalemedicine.medical_specialtyAdolescentBiopsy030230 surgeryNeuroendocrine tumorsGastroenterologyArticleYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineBiopsyTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]Multiple Endocrine Neoplasia Type 1medicineHumansMEN1Neoplasm MetastasisChildMultiple endocrine neoplasiaLymph nodeInsulinomaAgedNeoplasm StagingCause of deathAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHazard ratioDisease ManagementMiddle AgedPrognosismedicine.diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Pancreatic NeoplasmsPatient Outcome AssessmentNeuroendocrine Tumorsmedicine.anatomical_structure030220 oncology & carcinogenesisFemaleSurgeryDisease SusceptibilityNeoplasm GradingbusinessBiomarkers
researchProduct

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: A expression patterns and clinical implications

2018

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly improved overall survival. We hypothesize that this difference could be due to the immune response to the tumor, and as such, we investigated the expression of PD-1, PD-L1, and CD163 in a series of UCOGC. To this aim, 27 pancreatic UCOGCs (11 pure and 16 PDAC-associated), 5 extrapancreatic tumors with osteoclast-like giant cells and 10 pancreatic anaplastic carcinomas were immunostained using antibodies against PD-1, PD-L1, and CD163. In pancreatic UCOGCs, PD-L1 was expressed in neoplastic cells of 17 (63%) o…

Male0301 basic medicineIndianaProgrammed Cell Death 1 ReceptorOsteoclast; PDAC; Pancreatic Cancer; Tumor-Associated Macrophages; UCOGCOsteoclastsGiant CellsB7-H1 Antigen0302 clinical medicineTumor-Associated MacrophagesTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]LymphocytesAged 80 and overbiologyTumor-associated macrophagesCell DifferentiationMiddle AgedOsteoclast; Pancreatic cancer; PDAC; Tumor-associated macrophages; UCOGC; 2734ImmunohistochemistryEuropePhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisOsteoclastFemaleAntibodyCarcinoma Pancreatic DuctalAdult2734Antigens Differentiation MyelomonocyticReceptors Cell SurfaceUCOGCPathology and Forensic MedicinePancreatic Cancer03 medical and health sciencesImmune systemAll institutes and research themes of the Radboud University Medical CenterAntigens CDOsteoclastPD-L1Pancreatic cancerBiomarkers TumormedicineHumansHistiocyteAgedNeoplasm StagingPDACHistiocytesPancreatic cancermedicine.diseasePancreatic Neoplasms030104 developmental biologyGiant cellCancer researchbiology.proteinCD163
researchProduct

Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine

2019

Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients wer…

0301 basic medicineOncologymedicine.medical_specialtyCancer ResearchConcordanceprecision medicinepancreatic cancerReviewlcsh:RC254-282Circulating tumor cells (CTC)03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineLiquid biopsycfDNALiquid biopsyReceiver operating characteristicliquid biopsybusiness.industryCfDNAPrecision medicinePancreatic cancerPrecision medicinemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthCancer treatment030104 developmental biologyOncologycirculating tumor cells (CTC)030220 oncology & carcinogenesisMeta-analysisDiagnostic odds ratiobusinesscfDNA; circulating tumor cells (CTC); liquid biopsy; pancreatic cancer; precision medicine
researchProduct